Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced on Monday that its experimental drug, when combined with Novo ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

This article summarizes recent developments in the health sector, including major acquisitions, drug trial results, and ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 million upfront for a preclinical GLP-1 drug the company hopes will have a ...

Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China.

Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped patients lose weight while preserving lean muscle mass in a mid-stage ...